Ablation offers another treatment option for patients with metastatic colon cancer who are not candidates for resection, but the limited size of the ablation zone currently makes this technique… | Read More

Patients who were bridged/downstaged to orthotopic liver transplantation (OLT) by transarterial chemoembolization (TACE) or yttrium-90 (Y90) radioembolization had similar outcomes, even though Y90… | Read More

Interventional oncology is a rapidly evolving field, and clinicians are constantly adapting their clinical practice and office procedures to accommodate the latest advances. In this Q&A,… | Read More

In patients with hepatocellular carcinoma (HCC), a regimen of prophylactic dexamethasone prior to transcatheter arterial chemoembolization (TACE) is more effective at preventing fever, anorexia,… | Read More

Interventional radiologists provide cutting-edge treatments to patients with cancer, but excellent patient care involves more than a successful procedure. In this Q&A, Constantino Peña, MD,… | Read More

Spotlight

Clinical Interventional Oncology Course Director Ripal Gandhi, MD, Miami Cardiac and Vascular Institute (MCVI), shared his thoughts on the 9th annual Symposium in Hollywood Florida, Feb. 4-5, 2017.
Many interventional oncologists are exploring combined therapies for solitary hepatocellular cancer (HCC). The outcome of combining transarterial chemoembolization (TACE) and ablation has been reported, including two randomized, controlled trials;
Dr Alda Tam presented the session Understanding the Role of Biopsy at the 2017 Clinical Interventional Oncology Symposium. In this article, Dr Tam provides the reader with a full deciphering of her presentation. Here she explains the role of biopsy in the drug development timeline, the challenges faced by medical community, and how these challenges can be overcome.